Skip to main content

What the FDA labels say about taking them together

Abacavir and lopinavir/ritonavir

Lopinavir/ritonavir's FDA label of July 23, 2026 names abacavir in its drug interactions section; the abacavir labels PlainMeds reads (2) do not name lopinavir/ritonavir.

Check it at the source: the abacavir FDA label on DailyMed (effective July 17, 2025, Mylan Institutional Inc.); the lopinavir/ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).

What does the abacavir label say about lopinavir/ritonavir?

Abacavir's label (effective July 17, 2025) and its 1 other brand-application label do not name lopinavir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Abacavir Sulfate), Mylan Institutional Inc., effective July 17, 2025 (SPL set 80c1702a-973c-436a-90f8-69b29674dca0), via openFDA; the full label on DailyMed

What does the lopinavir/ritonavir label say about abacavir?

Lopinavir/ritonavir label, drug interactions

Concomitant Drug Class/Drug Name: Nucleoside Reverse Transcriptase Inhibitors: abacavir zidovudine; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ abacavir ↓ zidovudine; Clinical Comments: The clinical significance of this potential interaction is unknown.

Source: FDA drug label (Kaletra), AbbVie Inc., effective July 23, 2026 (SPL set 8290add3-4449-4e58-6c97-8fe1eec972e3), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

12Abacavir generic labelers
3Lopinavir/ritonavir generic labelers
AbacavirLopinavir/ritonavir
Labeled forHIVHIV
Boxed warningYesNo
Pharmacy cost (NADAC)$0.546 per tablet 300 mg tablet$4.46 per tablet 200-50 mg tablet
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?